Select Publications
Journal articles
2024, 'Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis', Blood Cancer Journal, 14, http://dx.doi.org/10.1038/s41408-024-01034-6
,2023, 'Once-weekly bortezomib as the standard of care in multiple myeloma: results from an international survey of physicians', Blood Cancer Journal, 13, http://dx.doi.org/10.1038/s41408-023-00937-0
,2023, 'A Phase I/II Single Arm Study of Belantamab Mafodotin, Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: Planned Interim Analysis of Safety and Efficacy. Amarc 19-02 Belacard Study', Blood, 142, pp. 2012 - 2012, http://dx.doi.org/10.1182/blood-2023-189005
,2023, 'Orthotopic Heart Transplantation Followed By Autologous Stem Cell Transplantation in Patients with Cardiac AL Amyloidosis: Results from a Single Centre Prospective Study', Blood, 142, pp. 3414 - 3414, http://dx.doi.org/10.1182/blood-2023-184319
,2023, 'Planned Interim Safety Analysis of the Phase 3 Randomized Trial of Selinexor and Lenalidomide Versus Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Patients with Newly Diagnosed Multiple Myeloma (ALLG MM23; Sealand)', Blood, 142, pp. 2023 - 2023, http://dx.doi.org/10.1182/blood-2023-185169
,2023, 'Retrospective Observational Study on Real-World Bortezomib Prescribing Patterns and Outcomes in Newly Diagnosed Multiple Myeloma', Blood, 142, pp. 544 - 544, http://dx.doi.org/10.1182/blood-2023-178950
,2023, 'Standard-of-Care Bortezomib Dosing in Multiple Myeloma: An International Survey of Physicians', Blood, 142, pp. 5073 - 5073, http://dx.doi.org/10.1182/blood-2023-173772
,2023, 'PB2698: MORE EFFICIENT DELIVERY OF HIGH-COST STANDARD-OF-CARE THERAPIES IN RELAPSED MULTIPLE MYELOMA USING REAL-TIME FEEDBACK OF PATIENT-REPORTED OUTCOME MEASURES: THE MY-PROMPT-2 TRIAL', HemaSphere, 7, pp. e68933f0 - e68933f0, http://dx.doi.org/10.1097/01.hs9.0000977464.68933.f0
,2023, 'Rates of Menstrual History-Taking and Counseling With Anticancer Treatments Are Low: People Who Menstruate Deserve Gender-Specific Cancer Care', JNCCN Journal of the National Comprehensive Cancer Network, 21, pp. 366 - 372, http://dx.doi.org/10.6004/jnccn.2022.7255
,2023, 'P-070 Failure to clear circulating tumor cells after one week of daratumumab, bortezomib and dexamethasone is associated with a reduced progression-free survival for myeloma patients', Clinical Lymphoma Myeloma and Leukemia, 23, pp. S73 - S73, http://dx.doi.org/10.1016/s2152-2650(23)01688-9
,2023, 'P-476 More efficient delivery of high-cost standard-of-care therapies in relapsed multiple myeloma using real-time feedback of patient-reported outcome measures: the MY-PROMPT-2 trial', Clinical Lymphoma Myeloma and Leukemia, 23, pp. S301 - S302, http://dx.doi.org/10.1016/s2152-2650(23)02093-1
,2022, 'Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review', British Journal of Haematology, 199, pp. 190 - 204, http://dx.doi.org/10.1111/bjh.18295
,2022, 'Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant', Blood Advances, 6, pp. 4949 - 4966, http://dx.doi.org/10.1182/bloodadvances.2022007103
,2022, 'P1573: VARIATION IN USE OF IMMUNOGLOBULIN AND IMPACT ON SURVIVAL IN MULTIPLE MYELOMA: A REPORT FROM THE AUSTRALIA/NEW ZEALAND (ANZ) AND ASIA-PACIFIC (APAC) MYELOMA AND RELATED DISEASES REGISTRIES (MRDR)', HemaSphere, 6, pp. 1454 - 1455, http://dx.doi.org/10.1097/01.hs9.0000849148.93868.54
,2022, 'P946: A PHASE I/II SINGLE ARM STUDY OF BELANTAMAB MAFODOTIN, CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA: AMARC 19-02 BELACARD STUDY.', HemaSphere, 6, pp. 836 - 837, http://dx.doi.org/10.1097/01.hs9.0000846652.51254.ac
,2022, 'Clinical characteristics and prognosis of cardiac amyloidosis defined by mass spectrometry-based proteomics in an Australian cohort', Internal Medicine Journal, 52, pp. 69 - 78, http://dx.doi.org/10.1111/imj.15072
,2022, 'OAB-048: An interim analysis of a phase I/II single arm study of belantamab mafodotin, carfilzomib and dexamethasone in patients with relapsed multiple myeloma: AMaRC 19-02 BelaCarD study', Clinical Lymphoma Myeloma and Leukemia, 22, pp. S29 - S30, http://dx.doi.org/10.1016/s2152-2650(22)00321-4
,2021, 'A Minority of Women of Child Bearing Potential Are Tested for Pregnancy before Chemoimmunotherapy: An Australian Cancer Centre Experience', BLOOD, 138, http://dx.doi.org/10.1182/blood-2021-154028
,2021, 'Systematic Omission of Pregnant and Lactating Women from Malignant Haematology Trials Perpetuates a Cycle of Exclusion, Data Shortage and Disadvantage', BLOOD, 138, http://dx.doi.org/10.1182/blood-2021-149354
,2021, 'Variation in Use of Immunoglobulin and Impact on Survival in Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)', Blood, 138, pp. 4757 - 4757, http://dx.doi.org/10.1182/blood-2021-147622
,2021, 'Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac-modified CD19 CAR T cells', Blood, 138, pp. 1504 - 1509, http://dx.doi.org/10.1182/blood.2021010813
,2021, 'Abnormal coagulation profiles in monoclonal gammopathy of undetermined significance: a case series', Pathology, 53, pp. 798 - 800, http://dx.doi.org/10.1016/j.pathol.2020.11.005
,2021, 'Chromosome microarray characterisation of chromosome arm 12p loss associated with complex molecular karyotype and recurrent adverse cytogenetic markers in multiple myeloma', Genes Chromosomes and Cancer, 60, pp. 668 - 677, http://dx.doi.org/10.1002/gcc.22975
,2021, 'COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement', Internal Medicine Journal, 51, pp. 763 - 768, http://dx.doi.org/10.1111/imj.15247
,2021, 'Weekly cyclophosphamide, subcutaneous bortezomib and dexamethathasone (CyBorD) for initial treatment of transplant-eligible patients with multiple myeloma: experience of two transplant centres', Bone Marrow Transplantation, 56, pp. 738 - 740, http://dx.doi.org/10.1038/s41409-020-01086-9
,2021, 'Two cases of successful autologous stem cell transplantation in patients with multiple myeloma and concurrent chronic myeloid leukaemia', Bone Marrow Transplantation, 56, pp. 514 - 516, http://dx.doi.org/10.1038/s41409-020-01025-8
,2021, 'Trends and Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study', Transplantation and Cellular Therapy, 27, pp. S399 - S401, http://dx.doi.org/10.1016/s2666-6367(21)00515-7
,2020, 'Australian and New Zealand Registry of Anticoagulation in the Obese: Prescribing Patterns, Drug Levels and Patient Outcomes', Blood, 136, pp. 21 - 21, http://dx.doi.org/10.1182/blood-2020-143150
,2020, 'Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study', Blood, 136, pp. 11 - 12, http://dx.doi.org/10.1182/blood-2020-138991
,2020, 'Weekly Cyclophosphamide, Subcutaneous Bortezomib and Dexamethathasone (CyBorD) for Initial Treatment of Transplant Eligible Patients with Multiple Myeloma: Experience of Two Transplant Centres', Blood, 136, pp. 42 - 43, http://dx.doi.org/10.1182/blood-2020-139269
,2020, 'Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic', Internal Medicine Journal, 50, pp. 667 - 679, http://dx.doi.org/10.1111/imj.14859
,2019, 'Massive Splenomegaly, An Unexpected Diagnosis', Pathology, 51, pp. S41 - S41, http://dx.doi.org/10.1016/j.pathol.2018.12.091
,2018, 'An unexpected diagnosis: leukaemic presentation of blastic plasmacytoid dendritic cell neoplasm with massive splenomegaly', Pathology, 50, pp. 773 - 775, http://dx.doi.org/10.1016/j.pathol.2018.05.007
,2018, 'Anticoagulation at the extremes of body weight: choices and dosing', Expert Review of Hematology, 11, pp. 817 - 828, http://dx.doi.org/10.1080/17474086.2018.1517040
,2018, 'HIT or miss? A comprehensive contemporary investigation of laboratory tests for heparin induced thrombocytopenia', Pathology, 50, pp. 426 - 436, http://dx.doi.org/10.1016/j.pathol.2017.11.089
,2018, 'Anticoagulation therapy in Australia', Annals of Blood, 3, pp. 48 - 48, http://dx.doi.org/10.21037/aob.2018.12.02
,2017, 'Clinical and laboratory diagnosis of heparin induced thrombocytopenia: an update', Pathology, 49, pp. 346 - 355, http://dx.doi.org/10.1016/j.pathol.2017.02.005
,2017, 'Acquired haemophilia A complicating alemtuzumab therapy for multiple sclerosis', BMJ Case Reports, 2017, http://dx.doi.org/10.1136/bcr-2017-223016
,2016, 'Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma', Journal of Hematology and Oncology, 9, http://dx.doi.org/10.1186/s13045-016-0278-x
,2013, 'Better estimates of survival for patients considering adjuvant chemotherapy after surgery for early non-small-cell lung cancer', Internal Medicine Journal, 43, pp. 424 - 429, http://dx.doi.org/10.1111/j.1445-5994.2012.02846.x
,2013, 'Using scenarios to explain life expectancy in advanced cancer: Attitudes of people with a cancer experience', Supportive Care in Cancer, 21, pp. 369 - 376, http://dx.doi.org/10.1007/s00520-012-1526-4
,2012, 'Using scenarios to explain survival time: Attitudes of people with a cancer experience.', Journal of Clinical Oncology, 30, pp. 9126 - 9126, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.9126
,Conference Papers
2011, 'P5-15-02: Patients' Views about How Oncologists Should Explain Prognosis in Advanced Cancer.', in Cancer Research, American Association for Cancer Research (AACR), http://dx.doi.org/10.1158/0008-5472.sabcs11-p5-15-02
,Conference Abstracts
2023, 'A minority of women of childbearing potential are tested for pregnancy before chemoimmunotherapy: an Australian cancer centre experience', in Internal Medicine Journal, http://dx.doi.org/10.1111/imj.16287
,2022, 'Role of Endomyocardial Biopsy and Mass Spectrometry for Precision in Cardiac Amyloid Subtyping: A Case Series', in Heart, Lung and Circulation, Elsevier BV, Vol. 31, pp. S99 - S100, http://dx.doi.org/10.1016/j.hlc.2022.06.123
,2021, 'A randomized, open-label, phase 3 study of low-dose selinexor and lenalidomide (Len) versus len maintenance post autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (NDMM): ALLG MM23, Sealand.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39, http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.TPS8055
,